ESMO 2023: Keytruda stars early with breast cancer data
No cancer conference would be complete without Merck & Co (NYSE: MRK) presenting a mountain of data on its blockbuster anti-PD-1 therapy Keytruda (pembrolizumab).
So it is no surprise to see Keytruda featuring on day one of the European Society of Medical Oncology (ESMO) Congress in Madrid, Spain.
"Results from KEYNOTE-756, together with our work across our oncology portfolio, demonstrate the progress we are making in earlier stages of certain cancers, including breast cancer"Among the data revealed is the first presentation of results from the neoadjuvant part of the Phase III KEYNOTE-756 trial investigating Keytruda alongside chemotherapy as neoadjuvant treatment, followed by Keytruda plus endocrine therapy as adjuvant treatment, for patients with high-risk, early-stage estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze